Plain-English translation of NCT07071051 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This pilot study is examining how a medication called Calaspargase Pegol (a newer form of an asparaginase-based drug) affects the body's ability to clot blood in children being treated for acute lymphoblastic leukemia. Researchers want to understand whether this medication causes fewer blood clotting problems compared to an older version that doctors have used for many years. By collecting blood samples and reviewing medical records, the team hopes to learn more about the safety of this treatment.
Some leukemia medicines can affect how blood clots, which can sometimes lead to dangerous bleeding or abnormal clotting. This study exists to understand whether the newer version of this medication is safer in this regard than the older version that has been used previously.
You likely qualify if…
You likely don't qualify if…
As a participant, you would have blood samples collected at certain points during your leukemia treatment. The researchers will also review your medical records to track any bleeding or clotting events you experience. The study is observational, meaning the doctors are watching and measuring rather than testing a new procedure — your cancer treatment itself remains the same.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States
Sponsor
Mayo Clinic
Enrollment target
~15 participants
Started
July 2025
Primary completion
December 2026
Age range
2 Years – 22 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Clinical Trials Referral Office
Mayo Clinic in Rochester
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.